Regarding the combination of anti-PD-1 antibodies and sorafenib, the combination therapy of nivolumab or pembrolizumab treatment in combination with sorafenib showed a better tumor control rate and prolonged PFS and OS in patients with unresectable HCC compared to anti-PD-1 monotherapy [130]. This evidence concerns the gene PDCD1 and hepatocellular carcinoma.